E
34.35
1.73 (5.30%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Insurance - Life (US) | 混合的 | 混合的 |
| Insurance - Life (全球的) | 混合的 | 混合的 | |
| 股票 | Ethos Technologies Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.6 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.28 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| 部门 | Financial Services |
| 行业 | Insurance - Life |
| 投资方式 | Small Value |
该时间范围内无数据。
该时间范围内无数据。
投资组合